Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

• Status: Withdrawn
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo, taken once daily in patients with Type 2 diabetes mellitus.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion criteria:

• Type 2 diabetes mellitus treated with diet and exercise or oral anti-diabetic treatment

• Body mass index between 20 and 40

• Females of childbearing potential must use adequate birth control.

Exclusion criteria:

• Subjects with previous use of insulin

• Type 1 diabetes

• Uncontrolled thyroid disease

• History of drug or alcohol abuse in the past year

• Any other clinically significant disease.